Skip to main content
. Author manuscript; available in PMC: 2021 Aug 18.
Published in final edited form as: Hypertension. 2021 Jul 19;78(3):816–830. doi: 10.1161/HYPERTENSIONAHA.120.15423

Figure 1. Genetic ablation of GPR35 (G-protein–coupled receptor 35) in aortic endothelial cells (ECs) improves cell functions.

Figure 1.

A, Representative fluorescent images showing characteristics of mouse aortic ECs (MAECs) by fluorescent staining of Dil-ac-LDL uptake and Ulex-lectin binding, CD31, VE-Cadherin, and eNOS (endothelial nitric oxide synthase). Scale bar, 100 μm. B, Real-time quantitative polymerase chain reaction (qPCR) confirmed the expression levels of Gpr35 in the GPR35WT and little to no expression in the GPR35KO MAECs. n=6–12, *P<0.05. C, Cell migration assay in GPR35WT and GPR35KO MAECs. n=6 per group. Scale bar, 400 μm. D, Three-dimensional (3D) tube formation assay in GPR35WT and GPR35KO MAECs. n=7 group. Scale bar, 400 μm. E, Cell proliferation assay in GPR35WT and GPR35KO MAECs. n=4 group. In B–E, Mann-Whitney U tests were used, *P<0.05 vs GPR35WT ECs, horizontal lines show mean±SD. DAPI indicates 4’,6-diamidino-2-phenylindole.